Skip to main content

Articles

“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime.” Read More ›


Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the National Comprehensive Cancer Network 20th Annual Conference, the newer drug, pazopanib, may have some benefit in total cost of care; survival outcomes were the same between drugs. Read More ›

Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy As­­sociation conference. Read More ›

Dr Papadopoulou and colleagues conducted a study evaluating treatment and prevention of medication associated ONJ, and presented their findings. Read More ›

The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeon’s Commission on Cancer. Read More ›


The Oncology Nursing Society (ONS) uses the definition of oncology nurse navigator (ONN) to include a professional registered nurse with oncology-specific clinical knowledge. Read More ›

There is nothing that pulls at my heart strings more than the sight of a young child dealing with a diagnosis of cancer. This issue of Conquering the Cancer Care Continuum™ focuses on pediatric cancer care, a challenging area of oncology management, but one in which amazing progress is being made. Read More ›

The birth of the pediatric hematology/oncology specialty can be traced back to the early part of the 20th century, when pediatricians began describing hematologic abnormalities in infants and children. Read More ›

Page 138 of 288